Advertisement

Topics

Latest "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Stories

11:14 EDT 18th September 2018 | BioPortfolio

Here are the most relevant search results for "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" found in our extensive news archives from over 250 global news sources.

More Information about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent for you to read. Along with our medical data and news we also list CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Clinical Trials, which are updated daily. BioPortfolio also has a large database of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Companies for you to search.

Showing "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Articles 1–25 of 4,900+

Tuesday 18th September 2018

STADA Arzneimittel AG: Voting results of the bondholders' meeting concerning the STADA-Bond 2015/2022

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond 18.09.2018 / 15:07 The issuer is solely responsible for the content of this announcement. Bad Vilbel, 18 September 2018 - STADA Arzneimittel Aktiengesellschaft ("STADA" or the "Issuer") today informed about the voting results of the meeting on 18 September 2018 (the "Bondholders' Meeting") of the bondholders (the "Bondholders") of the...


Molecular Assemblies Expands Patent Portfolio in Enzymatic DNA Synthesis

SAN DIEGO, September 18, 2018 — Molecular Assemblies, Inc. today announced the recent award of three patents, bringing the total to eight issued patents protecting the company’s proprietary enzymatic DNA synthesis technology in the United States and Europe. The three […] The post Molecular Assemblies Expands Patent Portfolio in Enzymatic DNA Synthesis appeared first on SynBioBeta.

Life Sciences Ontario Hosts Minister Navdeep Bains and Mayor Bonnie Crombie in Roundtable on Opportunities and Challenges Facing Canada’s Life Sciences Sector

On September 10th, 2018, Life Sciences Ontario hosted a roundtable discussion with the Minister of Innovation, Science and Economic Development, Navdeep Bains, and Mississauga Mayor Bonnie Crombie, along with key industry partners from the life sciences sector. The session, held at JLABS in MaRS, was led by Dr. Jason Field, President and CEO of Li...


Wolf Greenfield Named Patent Strategy & Management Firm of the Year at 2018 LMG Life Sciences Awards

Intellectual property law firm Wolf, Greenfield & Sacks, P.C. today announced that it was named the “Patent Strategy & Management Firm of the Year” at the 2018 LMG Life Sciences Awards, held at the Essex House in New York City on September 12, 2018. Now in its sixth year, the LMG Life Sciences Aw

AdaptVac and the emergence of virus-like particle vaccines in breast cancer

This week, AdaptVac announced the acceptance of a notice of allowance from the US Patent and Trademark Office (USPTO) for...Read More... The post AdaptVac and the emergence of virus-like particle vaccines in breast cancer appeared first on Pharmaceutical Technology.

Monday 17th September 2018

World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

Novartis International AG / World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's dise...

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same...  

Senate passes 'pay-for-delay' bill for biosimilars

InspireMD Announces Issuance of Two New U.S. Patents Covering Proprietary MicroNet Stent Jacket and Related Drug Eluting Technology

InspireMD (NYSE:NSPR), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, announced that the United States Patent and Trademark Office (USPTO) has issued US Patents 10,070,976 and 10,070,977 covering InspireMD’s proprietary MicroNet™ stent jacket combined with a stent scaffold and related drug eluting … ...

Brufsky Backs Biosimilars as Part of Oncology Treatment

Adam F. Brufsky, MD, PhD, discusses the differences between biosimilars and biologics, incentives for biosimilar use, and investigational agents on the horizon.

Evidence of insufficient quality of reporting in patent landscapes in the life sciences

This article was originally published by James A Smith, Zeeshaan Arshad, Hannah Thomas, Andrew J Carr & David A Brindley in Nature Biotechnology v35, pp 210–214 (2017) under a creative… The post Evidence of insufficient quality of reporting in patent l... The post Evidence of insufficient quality of reporting in patent landscapes in the life sciences appeared first on Biotechblog.

Nemaura Announces License Agreement for 3 New Transdermal Patch Developments, and 48 Hour Diclofenac Patch Debut at CPhI Madrid

Nemaura Pharma today announced it has entered into a license agreement with a Global Pharma Company to develop 3 new Transdermal Patch products. These patches address a multi-Billion dollar market and the agreement reflects the confidence placed in Nemaura’s ability to deliver complex dosage formulations. Previously Nemaura developed a daily transdermal ...

Geneus Health Granted Rare Groundbreaking Genetic Patent

GARS™ is the product of over 30 years of intense research and extensive analysis of the genetic link to addiction, performed by preeminent scientist Dr. Kenneth Blum. SAN ANTONIO, Texas (PRWEB) September 17, 2018 Geneus Health announced last week that after years of intensive review, they’ve completed the final process and have been issued a patent by the U.S. Patent Office, with an unprecede...

Cosmetics Weekly Trademark Review: Sept. 4 - Sept. 11

Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3...   

Teva wins FDA OK for crucial migraine drug

Vital to Teva's turnaround, Ajovy will challenge Novartis/Amgen's Aimovig

Nytt patent och ny CMO för Cereno scientific

Redo att gå in i fas II-studier.

STAT Plus: Can the whole CRISPR patent mess be resolved by companies writing checks? https://buff.ly/2OvgDSr 

STAT Plus: Can the whole CRISPR patent mess be resolved by companies writing checks? https://buff.ly/2OvgDSr 

Shuwen Biotech‘s PD-L1 Detection Kit Validated in Clinical Trials of Leading Drugs

Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs Deqing, China, September 17, 2018 / B3C newswire / -- Shuwen Biotech is the first in China to launch a locally manufactured proprietary PD-L1 test kit, which can accurately determine the expression status of PD-L1 in tumor tissues, and to provide laboratory te...

Mylan biosimilar to stress test Amgen Neulasta franchise, analyst predicts

One new Wall Street analysis showed the stakes are high, not just for both companies, but for gauging the disruptiveness of biosimilars in the U.S. overall.

STAT Plus: For CRISPR patents, the ugliest phase may be still to come

Can the whole CRISPR patent mess be resolved by companies writing checks?

Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO

Building Team to Transform Respiratory Virus Infection Management using Therapeutic Interfering Particles Virion Biotherapeutics announced today the appointments of Vanessa King, PhD, as President & Chief Executive Officer and Isabel Najera, PhD, as Chief Scientific Officer. Virion is developing proprietary first-in-class biologicals called Therape...

Sunday 16th September 2018

How to Protect your Big Ideas

The process of innovation has changed - it is much quicker than it used to be and it is more likely to rely on significant data. Instead of spending several years considering how a new technology performs under research conditions before starting to develop it, today’s entrepreneurs work to much shorter product development cycles. They are more likely to be testing several ideas simultaneou...

World's first passive anti-frosting surface fights ice with ice

(Virginia Tech) Researchers see immediate applications for the technology in the HVAC industry. Other applications include aerospace materials, like airplane wings. And with a little more development, car windshields are also an option for the anti-frosting technology, which has already been granted a full patent.

FDA Extends PDUFA Date for @AcordaNews's Inbrija, 3 Days after Company Loses Ampyra #Patent Appeal: http://ow.ly/2u6d30lO4po pic.twitter.com/PXYs6fIY5Q

FDA Extends PDUFA Date for @AcordaNews's Inbrija, 3 Days after Company Loses Ampyra #Patent Appeal: http://ow.ly/2u6d30lO4po  pic.twitter.com/PXYs6fIY5Q

InventHelp Inventor Creates a Post Setting Device (IPL-513)

PITTSBURGH, Sept. 16, 2018 /PRNewswire/ -- Two inventors from Silver Lake, Ind., wanted to fulfill the need for a precise post setting tool. The patent Read more...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks